I’m excited to start our advisory board, with the appointment of Dr. Mark Boguski. Since our initial financing in 2005, our investors have urged us to build the science advisory board.
So what took so long? Until now, it wasn’t necessary. We provided clear business value to pharma for a well-defined use case. An advisory board might have even been a distraction.
So what’s changed? As we build out the sequence data management (SDM) platform, we want to see beyond this year’s application of next generation sequencing (NGS), and make sure we understand where the industry is going.
Dr. Mark Boguski
Mark is a perfect advisor for this initiative. His practical experience at NCBI, Rosetta, and Novartis, and his current vantage point at Harvard Medical School and Beth Israel, places him squarely with a view to the future uses of sequence data in a clinical setting, and with firm grounding in the practical applications of sequence data for the past 20 years.
It’s an honor to have Mark join us as a scientific advisor. We hope to build a diverse advisory team to complement him with skills and experiences that reflect the diversity of talents converging on the digital revolution in biology.
